Bryan Tycango has been covered in these pages before, but last year he moved over to Stansberry… and that presumably means we’ll be hearing a lot more from him, thanks to Stansberry’s dramatically larger marketing budget. I covered teaser pitches for his Asian Growth Stocks newsletter, which was pretty heavily promoted during the “China miracle” […]
Articles
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
Thanks Doc for digging into Anavex a little more. Although for your readers sake I will expand. There primary drug ANA...
This is a rather incomplete analysis of Anavex 273. It omits the follow-up studies of the p2 alzheimers group which are...